Official ESCRS | European Society of Cataract & Refractive Surgeons


Outcomes of phacoemulsification combined with two iStent inject® trabecular microbypass stents and endocyclophotocoagulation

Search Title by author or title

Session Details

Session Title: Glaucoma Management

Session Date/Time: Monday 16/09/2019 | 16:30-18:00

Paper Time: 17:36

Venue: Free Paper Forum: Podium 4

First Author: : G. Ratnarajan UK

Co Author(s): :    A. Barata   M. Georgopoulos                          

Abstract Details


The aim of this study is to assess the safety and efficacy of phacoemulsification with two trabecular microbypass stents (iStent inject), and endocyclophotocoagulation (ECP) in glaucoma patients


tertiary hospital


In this prospective interventional study, two iStent inject stents (Glaukos Corporation, Laguna Hills, CA, USA) and ECP (treated area 300 degrees) were performed in conjunction with cataract surgery in 82 eyes of 70 subjects suffering from glaucoma (n = 77 primary open angle glaucoma, n = 5 chronic angle-closure glaucoma; mean mean deviation -7.33 ± 5.9) from October 2017 to December 2018. The intraocular pressure (IOP) and the number of glaucoma medications were assessed preoperatively, 1 week, 1 month, 3 months and 6 months after surgery and compared to preoperative findings.


The results showed an IOP decrease from 19.2 ± 4.3 to 13.3 ± 2.5, 13.6 ± 2.5 and 14.4  ± 2.7  mmHg after 3, 6 and 12 months follow-up, respectively. The glaucoma therapy was 2.1 ± 1.1 classes preoperatively and reduced to 1.4 ± 1.0, 1.3 ± 1.2 and 1.3± 1.4 over the same follow-up. No intra-or postoperative complications were reported.


iStent inject and ECP in conjunction with phacoemulsification can offer an effective IOP lowering and medication reduction to patients with mild to moderate glaucoma. There was a mean reduction of 0.8 hypotensive medications and 4.8 mmHg at 12 months compared to medicated baseline. It is a safe operation that provides a significant reduction of IOP and reduces medicine burden. Data beyond 12 months is required to assess long term efficacy.

Financial Disclosure:


Back to previous